已收盘 12-19 16:00:00 美东时间
-0.040
-0.15%
Lexicon Pharmaceuticals will present data on sotagliflozin's ability to reduce hypoglycemia risk in type 1 diabetes across kidney function levels during the ADA's 85th Scientific Sessions. The company will also share topline results from the PROGRESS Phase 2b study evaluating pilavapadin for diabetic peripheral neuropathic pain. Sotagliflozin is an SGLT2/SGLT1 inhibitor, and pilavapadin is an oral, non-opioid AAK1 inhibitor.
06-18 12:30